Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R1DH
|
||||
| Former ID |
DIB012958
|
||||
| Drug Name |
Oxybutynin hydrochloride
|
||||
| Synonyms |
Oxybutynin; Oxybutynin chloride; HOB-294; Oxybutynin hydrochloride (transdermal patch, overactive bladder); Oxybutynin hydrochloride (transdermal patch, overactive bladder), Hisamitsu
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Urinary incontinence [ICD9: 788.3; ICD10:N39.3, N39.4, R32] | Approved | [551871] | ||
| Company |
Watson Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H32ClNO3
|
||||
| Canonical SMILES |
C(C(=O)OCC#CCN(CC)CC)(c1ccccc1)(C1CCCCC1)O.Cl
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Muscarinic receptor | Target Info | Modulator | [525503], [551871] | |
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| References | |||||
| Ref 525503 | Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66. | ||||
| Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.